01/02/2026
This is a significant signal in Budget 2026.
The emphasis on biologics and biosimilars, the proposed Biopharma Shakti initiative (₹10,000 crore), expansion of NIPERs, creation of 1,000 accredited clinical trial sites, and strengthening of CDSCO together point to a serious intent to position India as a global biopharma manufacturing and innovation hub.
If executed well, this could accelerate affordable access to advanced therapies, strengthen regulatory science, and create long-term opportunities across research, manufacturing, clinical development, and education.
The real test will be implementation, but the direction is both timely and promising.
K Mukherjee
SFE-India HealthcareInnovation IndiaBiotech